Medivir announces positive top-line results from the MIV-711 osteoarthritis phase IIa extension studyRead more
Continued discussions with FDA on proposed remetinostat phase III design results in delay in planned start of studyRead more
Phase I/II study design of birinapant in combination with Keytruda® to be presented on June 4 at the ASCO Annual MeetingRead more
Quarterly report presentations
Medivir Corporate Governance documention.
Documentation from Medivir's Annual General Meetings.